{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:17Z","timestamp":1792783517500,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","id":[{"id":"https:\/\/ror.org\/02kqnpp86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Teriparatide is approved for the treatment of osteoporosis and is generally well-tolerated. However, concerns remain about a possible association with osteosarcoma, a rare but aggressive bone malignancy. This pharmacovigilance study aims to evaluate the reporting frequency of osteosarcoma associated with teriparatide in the Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual case safety reports (ICSRs) listing teriparatide as a suspected drug and osteosarcoma as an adverse event were extracted from the FAERS public dashboard up to 20 February 2025. Both descriptive and disproportionality analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 112,798 ICSRs involving teriparatide were retrieved, of which 29 were reported. Most cases involved female patients (72.4%) and older patients (48.3%). Almost all reports (96.6%) were classified as serious, with death being the most common outcome (44.8%). Of the reports with information on concomitant medications, 31% included five or more medications, with vitamins being the most common. The disproportionality analysis showed a significantly higher reporting frequency of osteosarcoma with teriparatide compared to all other drugs (reporting odds ratio, ROR: 15.31; 95% CI: 10.53\u201322.26). This signal remained consistent when the analysis was restricted to reports submitted since 2006 (ROR: 15.88; 95% CI: 10.92\u201323.09). The information component (IC) analysis confirmed this finding (IC: 3.56; 95% CI: 2.95\u20134), and similar results were observed for the post-2006 subset (IC: 3.60; 95% CI: 2.99\u20134.05). However, the analysis compared to another osteoporosis drug (romosozumab) did not confirm any safety signal for teriparatide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights a disproportionate signal between teriparatide use and osteosarcoma when compared to all other drugs but not compared to romosozumab. Based on this and considering that previous evidence did not support an increased risk, further research is warranted to better understand this association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00900-3","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:55:51Z","timestamp":1789671351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is teriparatide linked to osteosarcoma? A disproportionality analysis of the FAERS database"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1778-7083","authenticated-orcid":false,"given":"Nunzia","family":"Balzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4497-3836","authenticated-orcid":false,"given":"Raffaella","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8975-4019","authenticated-orcid":false,"given":"Ludovica Vittoria","family":"Laino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6875-0799","authenticated-orcid":false,"given":"Rosanna","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7107-4280","authenticated-orcid":false,"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-9889","authenticated-orcid":false,"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2554-0065","authenticated-orcid":false,"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-2408","authenticated-orcid":false,"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/S00198-021-05900-Y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049. https:\/\/doi.org\/10.1007\/S00198-021-05900-Y.","journal-title":"Osteoporos Int"},{"key":"900_CR2","unstructured":"FDA. Osteoporosis |From the FDA Office of Women\u2019s Health. 2024. https:\/\/www.fda.gov\/consumers\/womens-health-topics\/osteoporosis (accessed July 28, 2026)."},{"key":"900_CR3","unstructured":"FDA, Highlights of prescribing information -. FORTEO 2025. https:\/\/www.fda.gov\/medwatch. (accessed July 28, 2026)."},{"key":"900_CR4","doi-asserted-by":"publisher","unstructured":"Marin F, Ma YL. Teriparatide. Osteoporotic Fract Syst Skelet Disord Mech Assessment. Treat. 2024;339\u201359. https:\/\/doi.org\/10.1007\/978-981-16-5613-2_22.","DOI":"10.1007\/978-981-16-5613-2_22"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/J.TRRE.2017.08.002","volume":"31","author":"E L\u00f6fdahl","year":"2017","unstructured":"L\u00f6fdahl E, R\u00e5degran G. Osteoporosis following heart transplantation and immunosuppressive therapy. Transpl Rev. 2017;31:232\u20139. https:\/\/doi.org\/10.1016\/J.TRRE.2017.08.002.","journal-title":"Transpl Rev"},{"key":"900_CR6","doi-asserted-by":"publisher","unstructured":"Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, et al. Correction to: Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials (Archives of Osteoporosis, (2024), 19, 1, (89). https:\/\/doi.org\/10.1007\/s11657-024-01447-7). Arch Osteoporos 2024;19. https:\/\/doi.org\/10.1007\/S11657-024-01478-0.","DOI":"10.1007\/s11657-024-01447-7"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3949\/CCJM.88A.21011","volume":"88","author":"PD Miller","year":"2021","unstructured":"Miller PD, Lewiecki EM, Krohn K, Schwartz E, Teriparatide. Label changes and identifying patients for long-term use. Cleve Clin J Med. 2021;88:489\u201393. https:\/\/doi.org\/10.3949\/CCJM.88A.21011.","journal-title":"Cleve Clin J Med"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1359\/JBMR.2002.17.7.1151","volume":"17","author":"AH Tashjian","year":"2002","unstructured":"Tashjian AH, Chabner BA. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1\u201334 in the Treatment of Osteoporosis in Men and Postmenopausal Women. J Bone Min Res. 2002;17:1151\u201361. https:\/\/doi.org\/10.1359\/JBMR.2002.17.7.1151.","journal-title":"J Bone Min Res"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/S11914-008-0003-Y","volume":"6","author":"PD Miller","year":"2008","unstructured":"Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6:12\u20136. https:\/\/doi.org\/10.1007\/S11914-008-0003-Y.","journal-title":"Curr Osteoporos Rep"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/JBMR.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J Bone Min Res. 2021;36:244\u201351. https:\/\/doi.org\/10.1002\/JBMR.4188.","journal-title":"J Bone Min Res"},{"key":"900_CR11","unstructured":"FDA. Summary of product characteristics - FORTEO 1987."},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/S40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024;47:585\u201399. https:\/\/doi.org\/10.1007\/S40264-024-01423-7.","journal-title":"Drug Saf"},{"key":"900_CR13","unstructured":"FDA. FDA adverse events reporting system. - frequently asked questions n.d. https:\/\/fis.fda.gov\/extensions\/fpdwidgets\/2e01da82-13fe-40e0-8c38-4da505737e36.html (accessed July 28, 2026)."},{"key":"900_CR14","doi-asserted-by":"publisher","unstructured":"Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus. 2022;6. https:\/\/doi.org\/10.1002\/JBM4.10665\/7479075.","DOI":"10.1002\/JBM4.10665\/7479075"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/JBMR.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years. J Bone Min Res. 2012;27:2429. https:\/\/doi.org\/10.1002\/JBMR.1768.","journal-title":"J Bone Min Res"},{"key":"900_CR16","unstructured":"FDA. Clinical pharmacology Mechanism of Action - Forteo\u2009\u2013\u20092002 n.d. https:\/\/www.fda.gov\/drugsatfda (accessed July 28, 2026)."},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Sandusky G, Westmore M, ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32:426\u201338. https:\/\/doi.org\/10.1080\/01926230490462138.","journal-title":"Toxicol Pathol"},{"key":"900_CR18","doi-asserted-by":"publisher","unstructured":"Che J, Ren W, Chen X, Wang F, Zhang G, Shang P. PTH 1\u201334 promoted bone formation by regulating iron metabolism in unloading-induced bone loss. Front Endocrinol (Lausanne). 2023;13. https:\/\/doi.org\/10.3389\/FENDO.2022.1048818.","DOI":"10.3389\/FENDO.2022.1048818"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3892\/MCO.2019.1966","volume":"12","author":"T Ogawa","year":"2020","unstructured":"Ogawa T, Ohshika S, Yanagisawa M, Kurose A, Ishibashi Y. Teriparatide may accelerate the growth of a pre-existing malignant tumor in an elderly patient with osteoporosis: A case report. Mol Clin Oncol. 2020;12:144\u20137. https:\/\/doi.org\/10.3892\/MCO.2019.1966.","journal-title":"Mol Clin Oncol"},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1359\/JBMR.080807","volume":"23","author":"JL Vahle","year":"2008","unstructured":"Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M. Lack of Bone Neoplasms and Persistence of Bone Efficacy in Cynomolgus Macaques After Long-Term Treatment With Teriparatide [rhPTH(1\u201034)]. J Bone Min Res. 2008;23:2033\u20139. https:\/\/doi.org\/10.1359\/JBMR.080807.","journal-title":"J Bone Min Res"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/PDS.5103;ISSUE:ISSUE:DOI","volume":"29","author":"A Gilsenan","year":"2020","unstructured":"Gilsenan A, Midkiff K, Harris D, McQuay L, Hunter S, Kellier-Steele N, et al. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data. Pharmacoepidemiol Drug Saf. 2020;29:1616\u201326. https:\/\/doi.org\/10.1002\/PDS.5103;ISSUE:ISSUE:DOI.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/S00198-013-2470-Y","volume":"25","author":"UC Bang","year":"2014","unstructured":"Bang UC, Hyldstrup L, Jensen JEB. The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2014;25:639\u201344. https:\/\/doi.org\/10.1007\/S00198-013-2470-Y.","journal-title":"Osteoporos Int"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/S00223-018-0437-X","volume":"103","author":"N Napoli","year":"2018","unstructured":"Napoli N, Langdahl BL, Ljunggren \u00d6, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS). Calcif Tissue Int. 2018;103:359\u201371. https:\/\/doi.org\/10.1007\/S00223-018-0437-X.","journal-title":"Calcif Tissue Int"},{"key":"900_CR24","unstructured":"Teriparatide. Injection n.d."},{"key":"900_CR25","unstructured":"CHMP. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - FORSTEO n.d."},{"key":"900_CR26","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.5534\/WJMH.200099","volume":"39","author":"M De Martinis","year":"2021","unstructured":"De Martinis M, Sirufo MM, Polsinelli M, Placidi G, Di Silvestre D, Ginaldi L. Gender Differences in Osteoporosis: A Single-Center Observational Study. World J Mens Health. 2021;39:2287\u20134690. https:\/\/doi.org\/10.5534\/WJMH.200099.","journal-title":"World J Mens Health"},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/S00198-011-1725-8","volume":"23","author":"M Wong","year":"2012","unstructured":"Wong M, Wan X, Ruff V, Krohn K, Taylor K. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int. 2012;23:1445\u201352. https:\/\/doi.org\/10.1007\/S00198-011-1725-8.","journal-title":"Osteoporos Int"},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2:349\u201351. https:\/\/doi.org\/10.2165\/00128071-200102060-00001.","journal-title":"Am J Clin Dermatol"},{"key":"900_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/S00228-008-0494-6","volume":"64","author":"Y Zopf","year":"2008","unstructured":"Zopf Y, Rabe C, Neubert A, Ga\u00dfmann KG, Rascher W, Hahn EG, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64:999\u20131004. https:\/\/doi.org\/10.1007\/S00228-008-0494-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"900_CR30","doi-asserted-by":"publisher","unstructured":"Mascolo A, Di Napoli R, Balzano N, D\u2019Alessio E, Izzo I, Rossi F, et al. Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL. Front Pharmacol. 2023;14. https:\/\/doi.org\/10.3389\/FPHAR.2023.1229304.","DOI":"10.3389\/FPHAR.2023.1229304"},{"key":"900_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1723\/3245.32145","volume":"5","author":"G di Mauro","year":"2019","unstructured":"di Mauro G, Zinzi A, Vitiello F, Restaino M, Sportiello L, Rafaniello C, et al. Adverse drug reactions and gender differences: what changes in drug safety? J Sex- Gender-Specific Med. 2019;5:114\u201322. https:\/\/doi.org\/10.1723\/3245.32145.","journal-title":"J Sex- Gender-Specific Med"},{"key":"900_CR32","doi-asserted-by":"publisher","first-page":"866718","DOI":"10.3389\/FRAGI.2022.866718\/BIBTEX","volume":"3","author":"A Mylonas","year":"2022","unstructured":"Mylonas A, O\u2019Loghlen A. Cellular Senescence and Ageing: Mechanisms and Interventions. Front Aging. 2022;3:866718. https:\/\/doi.org\/10.3389\/FRAGI.2022.866718\/BIBTEX.","journal-title":"Front Aging"},{"key":"900_CR33","doi-asserted-by":"publisher","unstructured":"Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther. 2023;8. https:\/\/doi.org\/10.1038\/S41392-023-01502-8.","DOI":"10.1038\/S41392-023-01502-8"},{"key":"900_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2393267","author":"Z Dai","year":"2024","unstructured":"Dai Z, Zhang J, Tao Z, Gao R, Zhao Q. Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf. 2024. https:\/\/doi.org\/10.1080\/14740338.2024.2393267.","journal-title":"Expert Opin Drug Saf"},{"key":"900_CR35","doi-asserted-by":"publisher","unstructured":"Rossi C, Ruggiero R, Sportiello L, Pentella C, Gaio M, Pinto A, et al. Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction\u2019s Reporting? A Pharmacovigilance Study in Southern Italy. J Clin Med. 2022;11(202211). https:\/\/doi.org\/10.3390\/jcm11175104.","DOI":"10.3390\/jcm11175104"},{"key":"900_CR36","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17512433.2022.2132226","volume":"15","author":"R Ruggiero","year":"2022","unstructured":"Ruggiero R, Balzano N, Di Napoli R, Sullo MG, Rossi F, Capuano A, et al. Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19. Expert Rev Clin Pharmacol. 2022;15:1225\u201331. https:\/\/doi.org\/10.1080\/17512433.2022.2132226.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"900_CR37","doi-asserted-by":"publisher","first-page":"790740","DOI":"10.3389\/fphar.2021.790740","volume":"12","author":"M Gaio","year":"2021","unstructured":"Gaio M, Ferrajolo C, Zinzi A, Riccardi C, Di Filippo P, Carangelo L, et al. Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database \u2013 A Case Study. Front Pharmacol. 2021;12:790740. https:\/\/doi.org\/10.3389\/fphar.2021.790740.","journal-title":"Front Pharmacol"},{"key":"900_CR38","doi-asserted-by":"publisher","unstructured":"Liguori V, Gaio M, Zinzi A, Cagnotta C, Riccardi C, Docimo G et al. The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database. Biomed 2023, Vol 11, 2023;11. https:\/\/doi.org\/10.3390\/biomedicines11092538","DOI":"10.3390\/biomedicines11092538"},{"key":"900_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2443965","author":"R Di Napoli","year":"2024","unstructured":"Di Napoli R, Balzano N, Ruggiero R, Mascolo A, Scavone C, di Mauro G, et al. T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024. https:\/\/doi.org\/10.1080\/14740338.2024.2443965.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00900-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00900-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00900-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:55:55Z","timestamp":1789671355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00900-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":39,"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00900-3","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors. For this type of study, formal consent is not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}